Regeneron Pharmaceuticals Inc at J.P. Morgan 2019 Spring Biotech Conference Call Transcript
Welcome, and thank you all for standing by. I would like to inform all participants that this call is being recorded and will be available to clients of JPMorgan. Parts of this conference call may also be reproduced in JPMorgan research. If you have any objections, you may disconnect at this time.
This call is not intended for EEA clients that only subscribe for written research and members of the press are not permitted on this call. If you are with the press or are subject to MiFID II and do not have high touch access, please disconnect now. (Operator Instructions)
I would now like to turn the call over to Cory Kasimov. Please go ahead.
Great. Thank you, Sheena, and good afternoon, everyone. My name is Cory Kasimov. I'm a senior biotechnology analyst at JPMorgan, and I'm here with Matthew Holt from our team. Thanks for joining us for the latest installment of our 2019 Spring Biotech Conference Call series, where, today, it's our pleasure to be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |